KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) Meeting Abstract
| Authors: | Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R. F.; Siefker-Radtke, A. O.; Sonpavde, G.; De Wit, R.; Witjes, A.; Keefe, S. M.; Bajorin, D. F. |
| Abstract Title: | KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 263s |
| Language: | English |
| ACCESSION: | WOS:000404665407149 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS4576 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS4576 -- Source: Wos |
